A subsequent study by the same group tested the antagonistic potential of 1E10 clone in the context of ALL and showed that blocking of TSLPR represses proliferation and STAT activity in TSLPR+ BCP-ALL long term cultures (LTC) making it a potential therapeutic option for subset of BCP-ALL patients whose lymphoblasts express TSLPR (163) (Table 1). The gene discussed is SOAT1; the disease is acute lymphoblastic leukemia.